

REMARKS

This application has been amended in a manner that is believed to place it in condition for allowance at the time of the next Official Action.

Claims 85, 97, and 98 have been amended. Claims 107-114 and 119 have been canceled. Claims 85-89, 96-99, 103-106, 116-118, and 120 are currently pending in the present application.

In the outstanding Official Action, the listing of the claims was objected to because of the list of structures between claims 97 and 98. It was the intention of the previous amendment to the claims to cancel these structures. Accordingly, the structures have been deleted in the currently amended set of claims.

Claim 85 and dependent claims 86-89, 118, and 120 were objected to because claim 85 contained a period immediately before item (c). The period has been deleted from currently amended claim 85. Thus, applicants respectfully request that the objection to claim 85 and dependent claims 86-89, 118, and 120 be withdrawn.

Claim 98 and dependent claims 99 and 103-106 were objected to for apparently having minor informalities. As suggested in the Official Action, claim 98 has been amended to include "a" before "Ty982" and omit the second instance of "a compound of the formula:" in item b). Thus, applicants

respectfully request that the objection to claim 98 and dependent claims 99 and 103-106 be withdrawn.

Claims 107-114 and 119 were rejected under 35 USC §112, first paragraph, for not reasonably providing enablement for activating Ty982 lymphocytes in vivo. The rejection is moot, since claims 107-114 and 119 have been canceled.

Claims 96, 97, 116, and 117 were indicated as being allowable.


Claims 85-89, 98, 99, 103-106, 118, and 120 were indicated as being free of prior art.

Thus, in view of the above, applicants believe that the present application is in condition for allowance at the time of the next Official Action. Allowance and passage to issue on that basis are respectfully requested.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON


Philip A. DuBois, Reg. No. 50,696
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573

PD/lrs